Wound Care Biologics

Wound Care Biologics Comprehensive Study by Type (Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products), Topical Agents), Wound (Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers), Surgical and Traumatic Wounds, Burns), End User (Hospitals, Ambulatory Surgical Centers, Burn Centers and Wound Clinics) Players and Region - Global Market Outlook to 2030

Wound Care Biologics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Wound Care Biologics
The Wound Care Biologics Market is expected to grow in the future due to the rising geriatric population and the increasing number of burn cases. Availability of innovative wound care products boosting the market. Wound Care Biologics is an evolving segment of the advanced wound care market, which includes enzyme based formulations, Biologic Skin Substitutes, xenografts, and cell-based biogens to promote wound healing.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global Wound Care Biologics market is fragmented and the companies are exploring the market by adopting expansions, investments, new product launches, and collaborations as their preferred strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Wound Care Biologics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Smith & Nephew (United Kingdom), Integra LifeSciences Corporation (United States), Mölnlycke Health Care AB (Sweden), Wright Medical (United States), MiMedx Group (United States), Vericel Corporation (United States), Anika Therapeutics (United States), Osiris Therapeutics (United States) and Organogenesis (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are ACell(United States), Marine Polymer Technologies, Inc. (United States), Lavior Inc. (United States), Solsys Medical (United States) and Kerecis (Iceland).

Segmentation Overview
AMA Research has segmented the market of Global Wound Care Biologics market by Type (Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products) and Topical Agents) and Region.



On the basis of geography, the market of Wound Care Biologics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Wound, the sub-segment i.e. Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers) will boost the Wound Care Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Wound Care Biologics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Innovations in the Wound Care Biologics

Market Growth Drivers:
Rising Incidences of Burn Injuries and Increasing Geriatric and Diabetic population

Challenges:
Lack of Trained Physicians in Underdeveloped Economies

Restraints:
High Cost of Wound Care Biologic Products

Opportunities:
Rising R&D to Develop Quality Wound Care Biologics Products and High Growth Potential in Developing Countries

Market Leaders and their expansionary development strategies
In December 2023, Avita Medical and Revo Technologies entered into a strategic partnership to develop and commercialize next-generation regenerative medicine products for wound care.
In September 2023, Stemedica Inc. unveiled ACell+ PRP System, a point-of-care device that combines platelet-rich plasma (PRP) with their ACell+ matrix for enhanced wound healing.


Key Target Audience
Wound Care Biologics Manufacturers, Wound Care Biologics Distributors, Venture Capitalists, Various Research and Consulting Firms, Hospitals and Clinics and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products)
  • Topical Agents
By Wound
  • Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers)
  • Surgical and Traumatic Wounds
  • Burns

By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Burn Centers and Wound Clinics

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidences of Burn Injuries
      • 3.2.2. Increasing Geriatric and Diabetic population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Physicians in Underdeveloped Economies
    • 3.4. Market Trends
      • 3.4.1. Innovations in the Wound Care Biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Wound Care Biologics, by Type, Wound, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Wound Care Biologics (Value)
      • 5.2.1. Global Wound Care Biologics by: Type (Value)
        • 5.2.1.1. Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products)
        • 5.2.1.2. Topical Agents
      • 5.2.2. Global Wound Care Biologics by: Wound (Value)
        • 5.2.2.1. Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers)
        • 5.2.2.2. Surgical and Traumatic Wounds
        • 5.2.2.3. Burns
      • 5.2.3. Global Wound Care Biologics by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Burn Centers and Wound Clinics
      • 5.2.4. Global Wound Care Biologics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Wound Care Biologics (Price)
      • 5.3.1. Global Wound Care Biologics by: Type (Price)
  • 6. Wound Care Biologics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Smith & Nephew (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Integra LifeSciences Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mölnlycke Health Care AB (Sweden)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wright Medical (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MiMedx Group (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Vericel Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Anika Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Osiris Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Organogenesis (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Wound Care Biologics Sale, by Type, Wound, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Wound Care Biologics (Value)
      • 7.2.1. Global Wound Care Biologics by: Type (Value)
        • 7.2.1.1. Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products)
        • 7.2.1.2. Topical Agents
      • 7.2.2. Global Wound Care Biologics by: Wound (Value)
        • 7.2.2.1. Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers)
        • 7.2.2.2. Surgical and Traumatic Wounds
        • 7.2.2.3. Burns
      • 7.2.3. Global Wound Care Biologics by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Burn Centers and Wound Clinics
      • 7.2.4. Global Wound Care Biologics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Wound Care Biologics (Price)
      • 7.3.1. Global Wound Care Biologics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Wound Care Biologics: by Type(USD Million)
  • Table 2. Wound Care Biologics Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products) , by Region USD Million (2018-2023)
  • Table 3. Wound Care Biologics Topical Agents , by Region USD Million (2018-2023)
  • Table 4. Wound Care Biologics: by Wound(USD Million)
  • Table 5. Wound Care Biologics Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers) , by Region USD Million (2018-2023)
  • Table 6. Wound Care Biologics Surgical and Traumatic Wounds , by Region USD Million (2018-2023)
  • Table 7. Wound Care Biologics Burns , by Region USD Million (2018-2023)
  • Table 8. Wound Care Biologics: by End User(USD Million)
  • Table 9. Wound Care Biologics Hospitals , by Region USD Million (2018-2023)
  • Table 10. Wound Care Biologics Ambulatory Surgical Centers , by Region USD Million (2018-2023)
  • Table 11. Wound Care Biologics Burn Centers and Wound Clinics , by Region USD Million (2018-2023)
  • Table 12. South America Wound Care Biologics, by Country USD Million (2018-2023)
  • Table 13. South America Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 14. South America Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 15. South America Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 16. Brazil Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 17. Brazil Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 18. Brazil Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 19. Argentina Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 20. Argentina Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 21. Argentina Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 22. Rest of South America Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 23. Rest of South America Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 24. Rest of South America Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 25. Asia Pacific Wound Care Biologics, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 27. Asia Pacific Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 28. Asia Pacific Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 29. China Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 30. China Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 31. China Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 32. Japan Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 33. Japan Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 34. Japan Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 35. India Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 36. India Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 37. India Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 38. South Korea Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 39. South Korea Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 40. South Korea Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 41. Taiwan Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 42. Taiwan Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 43. Taiwan Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 44. Australia Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 45. Australia Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 46. Australia Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 50. Europe Wound Care Biologics, by Country USD Million (2018-2023)
  • Table 51. Europe Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 52. Europe Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 53. Europe Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 54. Germany Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 55. Germany Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 56. Germany Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 57. France Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 58. France Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 59. France Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 60. Italy Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 61. Italy Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 62. Italy Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 63. United Kingdom Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 64. United Kingdom Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 65. United Kingdom Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 66. Netherlands Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 67. Netherlands Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 68. Netherlands Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 69. Rest of Europe Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 70. Rest of Europe Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 71. Rest of Europe Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 72. MEA Wound Care Biologics, by Country USD Million (2018-2023)
  • Table 73. MEA Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 74. MEA Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 75. MEA Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 76. Middle East Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 77. Middle East Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 78. Middle East Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 79. Africa Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 80. Africa Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 81. Africa Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 82. North America Wound Care Biologics, by Country USD Million (2018-2023)
  • Table 83. North America Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 84. North America Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 85. North America Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 86. United States Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 87. United States Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 88. United States Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 89. Canada Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 90. Canada Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 91. Canada Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 92. Mexico Wound Care Biologics, by Type USD Million (2018-2023)
  • Table 93. Mexico Wound Care Biologics, by Wound USD Million (2018-2023)
  • Table 94. Mexico Wound Care Biologics, by End User USD Million (2018-2023)
  • Table 95. Wound Care Biologics: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Wound Care Biologics: by Type(USD Million)
  • Table 106. Wound Care Biologics Biologic Skin Substitutes (Human Donor Tissue-derived Products, Acellular animal-derived Products, Biosynthetic Products) , by Region USD Million (2025-2030)
  • Table 107. Wound Care Biologics Topical Agents , by Region USD Million (2025-2030)
  • Table 108. Wound Care Biologics: by Wound(USD Million)
  • Table 109. Wound Care Biologics Ulcers (Venous Ulcers, Diabetic Foot Ulcers, Pressure Ulcers, Other Ulcers) , by Region USD Million (2025-2030)
  • Table 110. Wound Care Biologics Surgical and Traumatic Wounds , by Region USD Million (2025-2030)
  • Table 111. Wound Care Biologics Burns , by Region USD Million (2025-2030)
  • Table 112. Wound Care Biologics: by End User(USD Million)
  • Table 113. Wound Care Biologics Hospitals , by Region USD Million (2025-2030)
  • Table 114. Wound Care Biologics Ambulatory Surgical Centers , by Region USD Million (2025-2030)
  • Table 115. Wound Care Biologics Burn Centers and Wound Clinics , by Region USD Million (2025-2030)
  • Table 116. South America Wound Care Biologics, by Country USD Million (2025-2030)
  • Table 117. South America Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 118. South America Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 119. South America Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 120. Brazil Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 121. Brazil Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 122. Brazil Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 123. Argentina Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 124. Argentina Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 125. Argentina Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 126. Rest of South America Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 127. Rest of South America Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 128. Rest of South America Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 129. Asia Pacific Wound Care Biologics, by Country USD Million (2025-2030)
  • Table 130. Asia Pacific Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 131. Asia Pacific Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 132. Asia Pacific Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 133. China Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 134. China Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 135. China Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 136. Japan Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 137. Japan Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 138. Japan Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 139. India Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 140. India Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 141. India Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 142. South Korea Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 143. South Korea Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 144. South Korea Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 145. Taiwan Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 146. Taiwan Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 147. Taiwan Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 148. Australia Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 149. Australia Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 150. Australia Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 154. Europe Wound Care Biologics, by Country USD Million (2025-2030)
  • Table 155. Europe Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 156. Europe Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 157. Europe Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 158. Germany Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 159. Germany Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 160. Germany Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 161. France Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 162. France Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 163. France Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 164. Italy Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 165. Italy Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 166. Italy Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 167. United Kingdom Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 168. United Kingdom Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 169. United Kingdom Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 170. Netherlands Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 171. Netherlands Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 172. Netherlands Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 173. Rest of Europe Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 174. Rest of Europe Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 175. Rest of Europe Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 176. MEA Wound Care Biologics, by Country USD Million (2025-2030)
  • Table 177. MEA Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 178. MEA Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 179. MEA Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 180. Middle East Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 181. Middle East Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 182. Middle East Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 183. Africa Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 184. Africa Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 185. Africa Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 186. North America Wound Care Biologics, by Country USD Million (2025-2030)
  • Table 187. North America Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 188. North America Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 189. North America Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 190. United States Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 191. United States Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 192. United States Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 193. Canada Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 194. Canada Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 195. Canada Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 196. Mexico Wound Care Biologics, by Type USD Million (2025-2030)
  • Table 197. Mexico Wound Care Biologics, by Wound USD Million (2025-2030)
  • Table 198. Mexico Wound Care Biologics, by End User USD Million (2025-2030)
  • Table 199. Wound Care Biologics: by Type(USD/Units)
  • Table 200. Research Programs/Design for This Report
  • Table 201. Key Data Information from Secondary Sources
  • Table 202. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Wound Care Biologics: by Type USD Million (2018-2023)
  • Figure 5. Global Wound Care Biologics: by Wound USD Million (2018-2023)
  • Figure 6. Global Wound Care Biologics: by End User USD Million (2018-2023)
  • Figure 7. South America Wound Care Biologics Share (%), by Country
  • Figure 8. Asia Pacific Wound Care Biologics Share (%), by Country
  • Figure 9. Europe Wound Care Biologics Share (%), by Country
  • Figure 10. MEA Wound Care Biologics Share (%), by Country
  • Figure 11. North America Wound Care Biologics Share (%), by Country
  • Figure 12. Global Wound Care Biologics: by Type USD/Units (2018-2023)
  • Figure 13. Global Wound Care Biologics share by Players 2023 (%)
  • Figure 14. Global Wound Care Biologics share by Players (Top 3) 2023(%)
  • Figure 15. Global Wound Care Biologics share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Smith & Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. Smith & Nephew (United Kingdom) Revenue: by Geography 2023
  • Figure 19. Integra LifeSciences Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. Integra LifeSciences Corporation (United States) Revenue: by Geography 2023
  • Figure 21. Mölnlycke Health Care AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 22. Mölnlycke Health Care AB (Sweden) Revenue: by Geography 2023
  • Figure 23. Wright Medical (United States) Revenue, Net Income and Gross profit
  • Figure 24. Wright Medical (United States) Revenue: by Geography 2023
  • Figure 25. MiMedx Group (United States) Revenue, Net Income and Gross profit
  • Figure 26. MiMedx Group (United States) Revenue: by Geography 2023
  • Figure 27. Vericel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Vericel Corporation (United States) Revenue: by Geography 2023
  • Figure 29. Anika Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Anika Therapeutics (United States) Revenue: by Geography 2023
  • Figure 31. Osiris Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 32. Osiris Therapeutics (United States) Revenue: by Geography 2023
  • Figure 33. Organogenesis (United States) Revenue, Net Income and Gross profit
  • Figure 34. Organogenesis (United States) Revenue: by Geography 2023
  • Figure 35. Global Wound Care Biologics: by Type USD Million (2025-2030)
  • Figure 36. Global Wound Care Biologics: by Wound USD Million (2025-2030)
  • Figure 37. Global Wound Care Biologics: by End User USD Million (2025-2030)
  • Figure 38. South America Wound Care Biologics Share (%), by Country
  • Figure 39. Asia Pacific Wound Care Biologics Share (%), by Country
  • Figure 40. Europe Wound Care Biologics Share (%), by Country
  • Figure 41. MEA Wound Care Biologics Share (%), by Country
  • Figure 42. North America Wound Care Biologics Share (%), by Country
  • Figure 43. Global Wound Care Biologics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Smith & Nephew (United Kingdom)
  • Integra LifeSciences Corporation (United States)
  • Mölnlycke Health Care AB (Sweden)
  • Wright Medical (United States)
  • MiMedx Group (United States)
  • Vericel Corporation (United States)
  • Anika Therapeutics (United States)
  • Osiris Therapeutics (United States)
  • Organogenesis (United States)
Additional players considered in the study are as follows:
ACell(United States) , Marine Polymer Technologies, Inc. (United States) , Lavior Inc. (United States) , Solsys Medical (United States) , Kerecis (Iceland)
Select User Access Type

Key Highlights of Report


Jan 2024 243 Pages 64 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Wound Care Biologics Quantitative research analysis
Wound Care Biologics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Smith & Nephew (United Kingdom), Integra LifeSciences Corporation (United States), Mölnlycke Health Care AB (Sweden), Wright Medical (United States), MiMedx Group (United States), Vericel Corporation (United States), Anika Therapeutics (United States), Osiris Therapeutics (United States) and Organogenesis (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Innovations in the Wound Care Biologics" is seen as one of major influencing trends for Wound Care Biologics Market during projected period 2023-2030.
The Wound Care Biologics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Wound Care Biologics Report?

Have a Query? Click Here

Other Related Reports

Pneumonia Therapeutics Comprehensive Study by Type (Vaccines, Anti-Infectives, Oxygen Therapy), Application (Hospital, Clinic, Medical Center, Other), Pneumonia Types (Hospital-acquired pneumonia (HA...
$ 3650
Bone Morphogenetic Protein Comprehensive Study by Type (Recombinant Human Bone Morphogenetic Protein (rhBMP) - 2, Recombinant Human Bone Morphogenetic Protein (rhBMP) -7), Application (Spinal Fusion,...
$ 3350
Spasticity Treatment Comprehensive Study by Type (Physical Treatment, Medicine Treatment), Application (Children, Adults), End User (Hospital, Research Laboratories, Others) Players and Region - Glob...
$ 3500
Tuberculosis Drug Comprehensive Study by Type (First-line Anti-TB Drugs, Second-line Anti-TB Drugs), Application (Active TB, Latent TB), End User (Hospital, Clinic, Durgstore), Testing (TB skin test ...
$ 3350
Inflammatory Bowel Disease Comprehensive Study by Type (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids), Application (Hospital, Drugs Stores), Route of A...
$ 3450
Organ Transplant Immunosuppressant Drugs Comprehensive Study by Type (Chemical Composition, Fungal Product, Biologics), Application (Liver Transplant, Kidney Transplant, Other Organ Transplant), Drug...
$ 3650